Cyclosporine in pediatric kidney transplantation

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S203-S207

  Pape, L ^a   Ehrich, J H H ^a   Offner, G ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; CHILD; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; GRAFT SURVIVAL; HIRSUTISM; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MICROEMULSION; NEPHROTOXICITY; PEDIATRIC SURGERY; PRIORITY JOURNAL;

EID: 1642401355     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.12.053     Document Type: Article

References (57)

1. Fine R.N., Malekzadeh M.H., Pennisi A.J., et al. Long-term results of renal transplantation in children. Pediatrics. 61:1978;641.
2. Grushkin C.M., Fine R.N. Growth in children following renal transplantation. Am J Dis Child. 125:1973;514.
3. Gradus D., Ettenger R.B. Renal transplantation in children. Pediatr Clin North Am. 29:1982;1013.
4. Borel J.F., Feurer C., Magnee C., et al. Effects of the new anti-lymphocytic peptide ciclosporine A in animals. Immunology. 32:1977;1017.
5. Calne R.Y., White D.J.G., Thiru S., et al. Ciclosporine A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323.
6. Calne R.Y., Rolles K., White D.J.G., et al. Ciclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs; 32 kidneys, 2 pancreases and 2 livers. Lancet. 2:1979;1033.
7. The European Ciclosporin Study Group: Ciclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 2:986, 1983.
8. The European Ciclosporin Study Group: Ciclosporin as a sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Preliminary results of a European multicentre trial. Lancet 2:57, 1982.
9. Starzl T.E., Iwatsuki S., Malatack J.J., et al. Liver and kidney transplantation in children receiving ciclosporine A and steroids. J Pediatr. 100:1982;681.
10. Conley S.B., Brewer E.D., Flechner S.M., et al. Renal transplantation using ciclosporine in pediatric patients 3 to 17 years old. Transplant Proc. 15:1983;2528.
11. Klare B., von Walter J., Hahn H., et al. Ciclosporine in renal transplantation in children. Lancet. 2:1984;692.
12. Conley S.B., Flechner S.M., Rose G., et al. Use of ciclosporine in pediatric renal transplant recipients. J Pediatr. 106:1985;45.
13. Hoyer P.F., Krohn H.P., Offner G., et al. Renal function after kidney transplantation in children a comparison of conventional immunosuppression with ciclosporine A. Transplantation. 43:1987;489.
14. Tejani A., Butt K.M.H., Khawar M.R., et al. Ciclosporine experience in renal transplantation in children. Kidney Int Suppl. 19:1986;38.
15. Conley S.B., Portman R.J., Lemire J.M., et al. Five years' experience with ciclosporine in children. Transplant Proc. 20:1988;280.
16. Offner G., Hoyer P.F., Brodehl J., et al. Ciclosporine A in paediatric kidney transplantation. Pediatr Nephrol. 1:1987;125.
17. Brodehl J., Offner G., Hoyer P.F., et al. Ciclosporin A in pediatric kidney transplantation and its effect on posttransplantation growth. Nephron. 44:1986;26.
18. Flechner S.M., Conley S.B., Van Buren C.T., et al. Impact of ciclosporine on renal function and growth in pediatric renal transplant recipients. Transplant Proc. 17:1985;1284.
19. Knight J.F., Roy L.P., Sheil A.G.R. Catch-up growth in children with successful renal transplants immunosuppressed with ciclosporin alone. Lancet. 1:1985;159.
20. Pennisi A.J., Costin G., Phillips L.S., et al. Linear growth in long-term renal allograft recipients. Clin Nephrol. 8:1977;412.
21. Chapman J.R., Giffiths D., Harding N.G.L., et al. Reversibility of ciclosporin nephrotoxicity after three months' treatment. Lancet. 1:1985;128.
22. Klintmalm G., Bohman S.O., Sundelin B., et al. Interstitial fibrosis in renal allografts after 12 to 46 months of ciclosporine treatment beneficial effects of low doses in early post-transplantation period. Lancet. 2:1984;950.
23. Hoyer P.F., Offner G., Wonigeit K., et al. Dosage of ciclosporine A in children with renal transplants. Clin Nephrol. 22:1984;68.
24. Hoyer P.F., Brodehl J., Ehrich J.H.H., et al. Practical aspects in the use of ciclosporin in pediatric nephrology. Pediatr Nephrol. 5:1991;630.
25. Ptachcinski R.J., Venkataramanan R., Rosenthal J.T., et al. The effect of food on ciclosporine absorption. Transplantation. 40:1985;174.
26. Holt D.W., Mueller E.A., Kovarik J.M., et al. The pharmacokinetics of Sandimmun Neoral a new oral formulation of ciclosporine. Transplant Proc. 26:1994;2935.
27. Kovarik J.M., Mueller E.A., van Bree J.B., et al. Ciclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation. 58:1994;658.
28. Kovarik J.M., Mueller E.A., van Bree J.B., et al. Reduced inter- and intraindividual variability in ciclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 83:1994;444.
29. Bökenkamp A., Offner G., Hoyer P.F., et al. Improved absorption of ciclosporin A from a new microemulsion formulation implications for dosage and monitoring. Pediatr Nephrol. 9:1995;196.
30. Bökenkamp A., Offner G., Hoyer P.F., et al. Excessive ciclosporine trough level variation with classic ciclosporine can be reduced with the new oral microemulsion formulation of ciclosporine. Transplant Proc. 28:1996;2273.
31. Portman R.J., Meier-Kriesche H.U., Swinford R., et al. Reduced variability of Neoral pharmacokinetic studies in pediatric renal transplantation. Pediatr Nephrol. 15:2000;2.
32. Soulillou J.P. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int. 46:1994;857.
33. Tejani A., Harmon W., Benfield M., et al. A randomized, prospective multicentre trial of T-cell antibody induction therapy in pediatric renal transplantation. Transplantation. 69:2000;S111.
34. Ault B.H., Honaker M.R., Osama Gaber A., et al. Short-term outcomes of thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol. 17:2002;815.
35. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 350:1997;1193.
36. Pape L., Strehlau J., Henne T., et al. Single-centre experience with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant. 17:2002;276.
37. Strehlau J., Pape L., Offner G., et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet. 356:2000;1327.
38. Pape L., Froede K., Stehlau J., et al. Alterations of ciclosporin A metabolism induced by mycophenolate mofetil. Pediatr Transplant. 7:2003;302.
39. Henne T, Latta K, Stehlau J, et al: Mycophenolate mofetil induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 76:1236, 2003.
40. Levy G., Burra P., Cavallari A., et al. Improved clinical outcome for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 73:2002;953.
41. Cantarovich M., Elstein E., der Varennes B., et al. Clinical benefit of Neoral dose monitoring with ciclosporine 2h post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 68:1999;1839.
42. Keshavamurthy M., Al Ahmadi I., Mohammed R.S. Single-center study utilizing C2 level as monitoring tool in de novo renal transplant recipients treated with Neoral. Transplant Proc. 33:2001;3098.
43. Maham N., Cardella C., Cole E. Optimization of ciclosporine exposure utilizing C2-level monitoring in de novo renal transplant recipients. Transplant Proc. 33:2001;2098.
44. Canadian Neoral Renal Transplantation Study Group. Absorption profile of ciclosporine microemulsion (Neoral) during the first two weeks after renal transplantation. Transplantation. 72:2001;1024.
45. Nashan B., Cole E., Levy G., et al. Clinical validation studies of Neoral C2 monitoring: a review. Transplantation. 73:2002;S3.
46. Mahalati K., Belitsky P., West K., et al. Approaching the therapeutic window for ciclosporine in kidney transplantation a prospective study. J Am Soc Nephrol. 12:2001;823.
47. Cole E., Midtvedt K., Johnston A., et al. Recommendations for the implementation of Neoral C2 monitoring in clinical practice. Transplantation. 73:2002;S19.
48. Levy G., Thervet E., Lake J., et al. Patient management by Neoral C2 monitoring an international consensus statement. Transplantation. 73:2002;S12.
49. Dello Strolongo L., Campagnano P., Federici G., et al. Ciclosporine A monitoring in children abbreviated area under curve formulas and C2 level. Pediatr Nephrol. 13:1999;95.
50. Mahalati K., Belitsky P., Sketris I., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time-curve its relationship to acute rejection and ciclosporine nephrotoxicity early after kidney transplantation. Transplantation. 68:1999;55.
51. Filler G., Mai I., Filler S., et al. Abbreviated ciclosporine AUCs on Neoral - the search continues. Pediatr Nephrol. 13:1999;98.
52. Meier-Kriesche H.U., Bonilla-Felix M.A., Ferris M.E., et al. A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients. Pediatr Nephrol. 13:1999;742.
53. Pape L., Lehnhardt A., Latta K., et al. Ciclosporin A monitoring by 2h-levels preliminary target levels in stable pediatric kidney transplant recipients. Clin Transplant. 17:2003;1.
54. Hoyer P. Therapeutic drug monitoring of ciclosporine A should we use the area under the concentration time-curve and forget trough levels? Pediatr Transplant. 4:2000;2.
55. Oellerich M., Armstrong V.W. Two-hour ciclosporine concentration determination an appropriate tool to monitor Neoral therapy? Ther Drug Monit. 24:2002;40.
56. Kahan B.D. The potential role of rapamycin in pediatric transplantation as observed from adult studies. Pediatr Transplant. 3:1999;175.
57. Vester U., Kranz B., Wehr S., et al. Everolimus (Certican) in combination with Neoral in pediatric renal transplant recipients interim analysis after 3 months. Transplant Proc. 34:2002;2209.